Tatva Chintan Pharma Chem Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/txt82lzr41ei5ljbeaq1ciff.pdf

Key Takeaways


SDA: The Core Earnings Driver That Stalled

Chintan Shah: "There is no lack of confidence in terms of whether this demand will ever happen or not, so in the backdrop, the demand continues to remain strong. Customer keeps on talking to us now quite frequently as well, but everyone is just waiting for that cycle to restart. So, it is just a matter of time and patience."

Margin Walk: Fixed Costs Met Falling Utilization

Chintan Shah: "Fuel and energy crisis, we don't expect to drop in a short term or a medium term, so that we will continue to absorb because for these kind of factors we also honestly cannot approach customers asking for a price raise because these are not actually significant part of the overall costing model which we normally discuss with customers."

Flame Retardant: Stabilized After a Painful Grind

Chintan Shah: "I will be honest that we have struggled a lot over the last couple of months to achieve the desired quality and yields on plant scale. But now we can confidently announce that our product quality can meet global standards."

Electrolyte Salts & Energy Storage: The Exponential Bet

Chintan Shah: "We expect very significant, significant is probably not the right word, we expect exponential growth in this area in next 3 years."

Monoglyme & New Product Pipeline

Chintan Shah: "That was a big task, big challenge which I am happy that we could do this and now we are submitting our samples for the battery application area with this specific quality requirements."

Demand Environment & Other Segments

Chintan Shah: "We are little fortunate because at the good time the SDA demand is now reviving back and also very good and fortunate part for us is typically the agrochemical demand is holding up quite well, so that particular sector is not seeing kind of any recessionary mode as of now."

Guidance & Commitments

CommitmentSpecificsTimeline
FY23 revenueIn excess of ₹400 Cr; may exceed if Chinese demand revives by FebruaryFY23
H2FY23 EBITDA margin20–22% rangeH2FY23
SDA demand normalizationBack to normal levels; FY24 revenue touching FY22 base of ~₹225 CrEnd of FY23 / FY24
Flame Retardant commercial revenueFirst full-scale orders (couple of hundred tons) from two customersDecember 2022, picking up January 2023
Flame Retardant FY24 volume1,400–1,800 metric tonsFY24
New capacity commissioningAdditional facilities at Dahej SEZEnd of Q3FY23
R&D facility expansionVadodara facility expansionEnd of FY23
Monoglyme battery-grade commercializationCommercial supplies begin after 5–6 month approval + ~4 months9–12 months from sample submission
Monoglyme revenue scale₹100 Cr2–3 years
Electrolyte salts exponential growthExponential growth trajectoryFY23 through FY25; 2025 as inflection year
Four new PASC products revenue potential₹800–₹1,000 Cr~4-year horizon
Inventory reduction₹60–65 Cr reductionBy end of FY23
New pharma intermediate commercializationCommercial supplies2024
New continuous flow product commercializationCommercial supplies2024

Key Metrics

MetricQ2 FY23
Revenue from operations₹90.1 cr, decline of 27% YoY, growth of 2% QoQ
EBITDA₹11.2 cr, decline of 68% YoY and 27% QoQ; includes forex loss of ₹3.19 cr
Operational EBITDA (ex-forex)₹14.36 cr, translating to operational EBITDA margin of 16%
EBITDA margin12% (reported), versus 29% in Q2 FY22; operational margin 16%
Net profit after tax₹7.1 cr, decline of 78% YoY and 27% QoQ
PAT margin8%, versus 26% in Q2 FY22
Exports₹59.4 cr, contributing 66% of revenue, declined 41% YoY
Full-year FY23 revenue guidanceIn excess of ₹400 cr, lowered from earlier ₹520–530 cr
H2FY23 EBITDA margin guidance20–22% expected
PTCs revenue₹32.6 cr, ~41% of revenue, growth of 69% YoY
Pharma and Agro Intermediates & Specialty Chemicals revenue₹42.7 cr, ~43% of revenue, growth of 45% YoY
SDAs revenue₹9.8 cr, ~9% of H1FY23 revenue, decline of 88% YoY
Electrolyte Salts revenue₹4.5 cr, ~6% of revenue, growth of 846% YoY
Total debt₹139.7 cr, debt-equity ratio of 0.29x, 85% working capital debt
IPO proceeds utilized₹133.8 cr of net ₹207.2 cr utilized as on 30 Sep 2022